Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Employment agrmnt
Quarterly results
Acq. announced
Director departure
Cogent Biosciences, Inc. (UMRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/03/2020 8-K Asset disposition
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : August 28, 2020 UNUM THERAPEUTICS INC. Delaware 001-38443 46-5308248 200 Cambridge Park Drive, Suite 3100 Cambridge, Massachusetts 02140 Registrant's telephone number, including area code 945-5576 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange...",
"Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO",
"Unaudited pro forma financial information"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy